Gynecology
News for Your Practice
Is elagolix safely effective at reducing heavy uterine bleeding in premenopausal women with uterine fibroids?
Phase 3 data showed that elagolix, plus low-dose add-back hormone therapy, reduced heavy menstrual bleeding at 6 months in 68.5%...
Clinical Review
Energy-based therapies in female genital cosmetic surgery: Hype, hope, and a way forward
Laser and radiofrequency devices are “out there” as therapeutic options for gyn cosmetic conditions, and some studies show...
Clinical Review
Assessing and treating sexual function after vaginal surgery
Keys to treatment include knowing the patient’s preoperative history of any dysfunction; understanding her concerns, needs, and...
From the Editor
Good news for ObGyns: Medical liability claims resulting in payment are decreasing!
Not as good news: Claims settling for a payment of greater than $1 million are increasing
Medical professional liability...
From the Journals
Ulipristal acetate tops placebo for uterine leiomyomas
Significantly greater improvements in physical and social activities were seen with both ulipristal doses, compared with placebo, from baseline to...
Gynecologic Oncology Consult
Discuss compounded bioidentical hormones and cancer risk
Patients who desire compounded bioidentical hormone preparations should be counseled that little is known about the safety of these preparations,...
Feature
Courts temporarily block Title X changes
The Trump administration wants to restrict funding from clinics that provide abortion counseling or that refer patients for abortion services.
Master Class
The genesis of vaginal anomalies
Master Class
Vaginal anomalies and their surgical correction
News
FDA orders companies to cease all sales of transvaginal mesh for POP repair
The manufacturers didn’t provide the required safety and efficacy data in their premarket applications.
From the Journals
Energy-based devices for vaginal rejuvenation described in FDA adverse event reports
The use of